UTHR EV/EBITDA: current value, 10-year range and year-by-year history
Cash & Leverage
UTHR's ev/ebitda is higher than 82% of the last 10 years.
EV/EBITDA History
UTHR EV/EBITDA by year
Yearly range of UTHR’s ev/ebitda from 2016 to 2026. Over the full period it ranged from 3.4 to 19.1, averaging 9.5.
| Year | Low | Average | High | Year-end |
|---|---|---|---|---|
| 2026 | 11.8 | 13.6 | 15.8 | 13.8 |
| 2025 | 7.0 | 9.7 | 13.7 | 12.4 |
| 2024 | 7.5 | 9.7 | 12.4 | 9.8 |
| 2023 | 8.7 | 10.3 | 13.4 | 9.0 |
| 2022 | 8.9 | 12.0 | 14.7 | 13.6 |
| 2021 | 10.9 | 15.0 | 19.1 | 14.9 |
| 2020 | 5.9 | 8.2 | 10.7 | 10.7 |
| 2019 | 5.1 | 5.6 | 6.1 | 5.6 |
| 2018 | 3.4 | 4.7 | 6.2 | 5.2 |
| 2017 | 4.0 | 4.8 | 6.1 | 5.2 |
| 2016 | 3.9 | 4.7 | 5.4 | 5.3 |
Get notified when UTHR EV/EBITDA crosses a threshold
Free — one alert setup, notifications by push, Telegram, or Discord.
An acquisition-style valuation multiple: Enterprise Value (market cap + net debt) divided by operating earnings before accounting adjustments. Compares companies fairly regardless of their capital structure.
(Market Cap + Net Debt) / EBITDAUnlike P/E, this metric accounts for debt — two companies with identical operations but different leverage will show similar EV/EBITDA. Low vs history suggests the total business is modestly priced.
- EBITDA ignores capital expenditure. For asset-heavy businesses (airlines, mining, utilities), this understates the real cost — use EV/EBIT or EV/FCF instead.
- Large acquisitions temporarily spike net debt and can distort the ratio for 1–2 years during integration.
Is UTHR EV/EBITDA High or Low Right Now?
United Therapeutics Corporation's EV/EBITDA is currently 13.8, which is historically pricey relative to its 10-year historical range. The 10-year median EV/EBITDA for UTHR is approximately 9.6. See all UTHR valuation metrics →
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.